• Media type: E-Article
  • Title: Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines
  • Contributor: Michalik, Stephan; Siegerist, Florian; Palankar, Raghavendra; Franzke, Kati; Schindler, Maximilian; Reder, Alexander; Seifert, Ulrike; Cammann, Clemens; Wesche, Jan; Steil, Leif; Hentschker, Christian; Gesell-Salazar, Manuela; Reisinger, Emil; Beer, Martin; Endlich, Nicole; Greinacher, Andreas; Völker, Uwe
  • imprint: Ferrata Storti Foundation (Haematologica), 2022
  • Published in: Haematologica
  • Language: Not determined
  • DOI: 10.3324/haematol.2021.280154
  • ISSN: 1592-8721; 0390-6078
  • Origination:
  • Footnote:
  • Description: <jats:p>Vector-based SARS-CoV-2 vaccines have been associated with vaccine- induced thrombosis with thrombocytopenia syndrome (VITT/TTS), but the causative factors are still unresolved. We comprehensively analyzed the ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Johnson and Johnson) vaccines. ChAdOx1 nCoV-19 contains significant amounts of host cell protein impurities, including functionally active proteasomes, and adenoviral proteins. A much smaller amount of impurities was found in Ad26.COV2.S. Platelet factor 4 formed complexes with ChAdOx1 nCoV-19 constituents, but not with purified virions from ChAdOx1 nCoV-19 or with Ad26.COV2.S. Vascular hyperpermeability was induced by ChAdOx nCoV-19 but not by Ad26.COV2.S. These differences in impurities together with EDTAinduced capillary leakage might contribute to the higher incidence rate of VITT associated with ChAdOx1 nCoV-19 compared to Ad26.COV2.S.</jats:p>
  • Access State: Open Access